Abstract:INTRODUCTION AND AIMS:We previously evaluated the effects of pre-dilution on-line hemodiafiltration (pre-HDF) and post-dilution on-line HDF (post-HDF) using markers, including interleukin (IL)-6, intercellular adhesion molecule (ICAM)-1,and pentraxin (PTX)-3, and lymphocyte stimulation test.We reported that pre-HDF was more friendly to the body than post-HDF.The previous study was performed with a blood flow rate (Qb) of 200 mL/min and substitution fluid volume (Vs) of 10 L in post-HDF.In this study, biocompatibility of pre-HDF and post-HDF was examined at a 50% increased Qb in both modes and a 200% increased Vs in post-HDF.METHODS: Six stable dialysis patients (M/F: 5/1; age 54.7 6 13.3 years) were enrolled.Treatment was performed in the order of hemodialysis (HD), post-HDF, pre-HDF, post-HDF, and HD.Each treatment mode was continued for 2 weeks (4hrs treatment time) .Laboratory tests were performed on the last day of each treatment mode.The Qb was 300 mL/min and the total dialysate flow rate was 600 mL/min for each treatment mode.The Vs was set as 60 L/s in pre-HDF and 20 L/s in post-HDF.The dialyzer used was PS membrane filter with a membrane surface area of 2.1 m 2 .Removal performance was evaluated based on removal rates of small molecules (urea N, creatinine, phosphorus) and low molecular weight proteins (LMWP) (b 2 -microglobulin [MG], prolactin, a 1 -MG).Biocompatibility was evaluated by measuring changes in pre-dialysis values of high-sensitivity C-reactive protein (CRP), IL-6, PTX-3, b-thromboglobulin (TG), and p-selectin and their change rates before and after dialysis.Additionally, lymphocyte function was evaluated using lymphocyte transformation test (mitogen: PHA and ConA).Statistical analysis was performed using Friedman test for intragroup comparison.Statistical significance was set at p < 0.05.RESULTS: The removal efficiency of small molecules was significantly higher in post-HDF than in pre-HDF.Removal rates of b 2 -MG were not significantly different between the two modes, while those of prolactin and a 1 -MG were significantly higher in post-HDF than in pre-HDF.The results of biocompatibility test showed that changes in pre-dialysis values and change rates of CRP, IL-6, and PTX-3 levels before and after dialysis were not significantly different between modes.The change rates of platelet activation markers, such as p-selectin and b-TG, also did not differ significantly between modes.Lymphocyte transformation test showed that the change rates in stimulation index of PHA-and ConA-stimulated cultures were not significantly different between the modes.This study did not support superiority of pre-HDF over post-HDF in terms of biocompatibility.The first possible reason is that accurate comparison of changes in cytokines might have been difficult without controlling removal efficiency of LMWP because cytokine production and removal occur simultaneously during HDF.Second, the higher total blood flow rate (560 mL/min), which was induced from Qb 300 mL/min and Qs 260ml/min (Vs: 60 L), than that in the previous study (440 mL/min) might have led to an increase in shear stress in the fiber, resulting in negative effects on biocompatibility.CONCLUSIONS: In this study, comparison of biocompatibility between pre-HDF and post-HDF yielded no significant difference.

Effectiveness Observation of Sequential Hemodialysis without Heparinum in Treatment of Uremia Complicated by In-tracerebral Hemorrhage

The Design and Clinical Application of a New Type of Disposable Heparin Free Dialysis Tube

A clinical study of high-dose urokinase for the treatment of the patients with hypertension induced ventricular hemorrhage

Influence on curative effect and blood brain barrier function of minimally invasive puncture drainage in treatment of patients with hypertensive intra-cerebral hemorrhage

Effect of minimally invasive surgery for intracerebral hemorrhage: a single center retrospective analysis

Clinical Observation of External Ventricular Drainage Combined with Lumbar Cistern Drainage in Treatment of Patients with Hypertensive Intraventricular Hemorrhage

Effect of Hyperbaric Oxygen Combined with Ganglion Glycosides on Thrombin, Serum Myelin Basic Protein and D-dimer in Patients with Intracerebral Hemorrhage

Application of Continuous Veno-Venous Hemodiafiltration to Severely Acute Renal Failure after Cardiac Surgery

Effect of the Intensity of Continuous Renal Replacement Therapy in Patients with Sepsis and Acute Kidney Injury: a Single-Center Randomized Clinical Trial

Acute Effect of One Session of Hemodiafiltration with Endogenous Reinfusion on Uremic Toxins and Inflammatory Mediators.

A Clinical study on the Effect of Peritoneal Dialysis and Hemodialysis on the Microinflammatory State and Quality of Life in Patients with Chronic Renal Failure

Clinical Observation of Improving Uremia Combined with Hyperparathyroidism by Treatment of Hemoperfusion Series Coupling Hemodiafiltration

Effect of hemodialysis combined with blood perfusion and comprehensive nursing intervention on the levels of interleukin-6, C-reactive protein and β2-microglobulin in patients with diabetic nephropathy

Comparison of the Effects of Plasma Exchange Plus Continuous Blood Purfication and Intermittent Hemodialysis on Patients with Serious Uremic Encephalopathy

Effect of continuous renal replacement therapy with regional citrate anticoagulation on intracerebral hemorrhage complicated with acute renal injury

Removal of inflammatory factors and prognosis of patients with septic shock complicated with acute kidney injury by hemodiafiltration combined with HA330‐II hemoperfusion

Treatment of Intraventricular Hemorrhage by Intraventricular Infusion of Urokinase

Clinical observation of small volume replacement of cerebrospinal fluid in the treatment of acute subarachnoid hemorrhage

Comparison Between Endoscopy and Conventional Drainage Operations in Treatment of 66 Cases with Hypertensive Intraventricuar Hemorrhage

Effect of the combination of HA380 hemoperfusion with CVVHDF on inflammatory indices and microcirculation in early septic shock

SP472ARGATROBAN ANTICOAGULATION THERAPY IN SEPSIS PATIENTS WITH THROMBOCYTOPENIA RECEIVING RENAL REPLACEMENT THERAPY